Metastatic and localised mismatch repair-deficient (dMMR) tumours are exquisitely sensitive to immune checkpoint blockade (ICB). The ability of ICB to prevent dMMR malignant or pre-malignant neoplasia development in patients with Lynch syndrome is unknown.
The data has implications for immunopreventative strategies and provide insight into the immunobiology of dMMR tumours.
It would be beneficial to evaluate the immunoediting effects of immunotherapy treatment amongst patients with LS and the implications they may have for future vaccine and immune intervention studies.
Lynch Syndrome Ireland 